Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 17/20 | 0.50 |
| ▸ | CYP17A1 | P05093 | 8/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | SCN1A | P35498 | 1/20 | 0.36 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.36 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1439686 | 0.83 | CYP19A1 (0.50) | CYP19A1CYP17A1TDP1SIGMAR1SCN1A | |
| SCHEMBL11195088 | 0.78 | CYP19A1 (0.53) | CYP19A1CYP17A1TDP1SIGMAR1SCN1A | |
| SCHEMBL1439303 | 0.78 | CYP19A1 (0.48) | CYP19A1CYP17A1TDP1SIGMAR1SCN1A | |
| SCHEMBL6404865 | 0.76 | CYP19A1 (0.59) | CYP19A1CYP17A1TDP1SIGMAR1SCN1A | |
| SCHEMBL17213197 | 0.76 | CYP19A1 (0.49) | CYP19A1CYP17A1TDP1SIGMAR1SCN1A | |
| SCHEMBL4598002 | 0.76 | CYP19A1 (0.49) | CYP19A1CYP17A1TDP1SIGMAR1SCN1A | |
| SCHEMBL17213209 | 0.76 | CYP19A1 (0.49) | CYP19A1CYP17A1TDP1SIGMAR1SCN1A | |
| SCHEMBL1438873 | 0.76 | SCN1A (0.53) | CYP19A1CYP17A1TDP1SIGMAR1SCN1A | |
| SCHEMBL4597731 | 0.76 | CYP19A1 (0.49) | CYP19A1CYP17A1TDP1SIGMAR1SCN1A | |
| SCHEMBL18503894 | 0.75 | CYP19A1 (0.60) | CYP19A1CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008065408-A9 | MODULATION OF PROSTAGLANDIN/CYCLOOXYGENASE METABOLIC PATHWAYS | HUNTER-FLEMING LIMITED (GB) | 2011-03-03 | — | — | WO | disclosed |
| EP-2097079-A2 | MODULATION OF PROSTAGLANDIN/CYCLOOXYGENASE METABOLIC PATHWAYS | Hunter-Fleming Limited (GB) | 2009-09-09 | — | — | EP | disclosed |
| WO-2008065408-A2 | MODULATION OF PROSTAGLANDIN/CYCLOOXYGENASE METABOLIC PATHWAYS | HUNTER-FLEMING LIMITED (GB) | 2008-06-05 | — | — | WO | disclosed |
| EP-1848426-A2 | TRICYCLIC CYTOPROTECTIVE COMPOUNDS | Hunter-Fleming Limited (GB) | 2007-10-31 | — | — | EP | disclosed |
| WO-2006082409-A2 | TRICYCLIC CYTOPROTECTIVE COMPOUNDS | HUNTER-FLEMING LIMITED (GB) | 2006-08-10 | — | — | WO | disclosed |